Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 4/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTGFR | P43088 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 3/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | BLVRB | P30043 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907481 | 0.88 | HTR5A (0.40) | HTR5ACSNK2A2CSNK2BLMNASMN1; SMN2 | |
| SCHEMBL9907401 | 0.87 | HTR5A (0.46) | HTR5ACSNK2A2CSNK2BDHODH | |
| SCHEMBL9907444 | 0.87 | HTR5A (0.47) | HTR5ALMNASMN1; SMN2 | |
| SCHEMBL9907400 | 0.86 | HTR5A (0.54) | HTR5ADHODH | |
| SCHEMBL9907494 | 0.85 | HTR5A (0.55) | HTR5ACSNK2A2CSNK2BLMNASMN1; SMN2 | |
| SCHEMBL9907448 | 0.84 | HTR5A (0.47) | HTR5ALMNASMN1; SMN2PTGFR | |
| SCHEMBL9907833 | 0.84 | HTR5A (0.72) | HTR5A | |
| SCHEMBL9907360 | 0.83 | ALDH1A1 (0.50) | LMNASMN1; SMN2MGAM | |
| SCHEMBL9907361 | 0.82 | HTR5A (0.49) | HTR5ALMNA | |
| SCHEMBL9907737 | 0.81 | HTR5A (0.71) | HTR5ACSNK2A2CSNK2BPTGFRDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885CSNK2A2 4132/4885CSNK2B 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.